Kim Richard, Byer Jenifer, Saif Muhammad Wasif
H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
JOP. 2012 Mar 10;13(2):180-1.
Germline mutations in BRCA genes are associated with increased risk of pancreatic cancer. There are pre clinical data which suggests that DNA cross linking agents should be used in pancreatic cancer patients with BRCA mutations. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of pancreatic cancer with BRCA mutation. Only one study (Abstracts #217) was presented and it is described here.
BRCA基因的种系突变与胰腺癌风险增加相关。有临床前数据表明，DNA交联剂应用于患有BRCA突变的胰腺癌患者。本综述是对2012年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会关于BRCA突变胰腺癌治疗最新进展的更新。仅展示了一项研究（摘要#217）并在此进行描述。
